BERKELEY, Calif., June 26, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the appointment of Stephen Sherwin, M.D., to the company's board of directors. The addition of Dr. Sherwin increases the number of directors from six to seven.
"We are extremely pleased to have Steve, a luminary in medical oncology and biotechnology, join our board," said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. "He has been at the forefront of immuno-oncology research for many years and we believe his early efforts in the field have paved the way for companies like Aduro to make additional therapeutic advances. We look forward to his contributions as we move forward with our research and development efforts directed toward providing new and better treatment options for cancer patients with our novel LADD and CDN immunotherapy platform technologies."
Dr. Sherwin currently divides his time between advisory work in the life science industry, patient care and teaching medical oncology. He is a clinical professor of medicine at the University of California, San Francisco, and a volunteer attending physician in hematology-oncology at San Francisco General Hospital. He currently serves as a director at Biogen, Neurocrine Biosciences, Rigel Pharmaceuticals, Verastem and Vical and is an advisor to oncology-focused life science companies. Previously, Dr. Sherwin was chairman and chief executive officer of Cell Genesys, an immuno-oncology company, from 1990 until the company's merger in 2009 with BioSante Pharmaceuticals, (now ANI Pharmaceuticals). He was also a co-founder and chairman of Abgenix, an antibody company, which was acquired by Amgen in 2006, and co-founder and chairman of Ceregene, a gene therapy company acquired by Sangamo Biosciences in 2013. Earlier in his career, Dr. Sherwin was vice president of clinical research at Genentech. Dr. Sherwin also served on the board of directors of the Biotechnology Industry Organization from 2001 to 2014 and as chairman of the organization from 2009 to 2011 and was a member of the President's Council of Advisors in Science and Technology Working Group on Drug Development from 2011 to 2013. Dr. Sherwin holds a B.A. in biology from Yale University, where he graduated summa cum laude, and an M.D. from Harvard Medical School. He is board-certified in internal medicine and medical oncology and a fellow of the American College of Physicians.
Aduro Biotech, Inc. is a clinical-stage immuno-oncology company focused on the development of technology platforms to stimulate an immune response against cancer. Aduro's lead platform is based on proprietary strains of live-attenuated, double-deleted (LADD) Listeria monocytogenes that induce a potent innate immune response and have been engineered to express tumor-associated antigens to induce tumor-specific T cell-mediated immunity. Aduro has received Breakthrough Therapy designation from the FDA for its lead LADD regimen, CRS-207 in combination with GVAX Pancreas in pancreatic cancer. The company is evaluating the proprietary immuno-oncology combination in the ongoing Phase 2b ECLIPSE clinical trial and has additional ongoing clinical trials with its LADD platform in mesothelioma and glioblastoma. The company is also developing clinical candidates using cyclic dinucleotide (CDN) synthetic small molecule immune modulators that are designed to activate the intracellular STING receptor, a central mediator of the innate immune response. For more information, please visit www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential for our technology and our on-going clinical trials. In some cases you can identify these statements by forward-looking words such as "believe," "look forward" or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net operating losses and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to use and expand our technology platforms to build a pipeline of product candidates, our dependence on our lead product candidate, CRS-207, and GVAX Pancreas, our ability to obtain and maintain regulatory approval of our product candidates, our inability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, our reliance on third parties, and our ability to obtain and adequately protect intellectual property rights for our product candidates. We discuss many of these risks in greater detail under the heading "Risk Factors" contained in the most recent Form 10-Q which is on file with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CONTACT: Sylvia Wheeler
SVP, Corporate Affairs
510 809 9264
925 202 6211